vs
Prestige Consumer Healthcare Inc.（PBH）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是Ribbon Communications Inc.的1.7倍（$283.4M vs $162.6M），Ribbon Communications Inc.净利率更高（54.8% vs 16.5%，领先38.3%），Prestige Consumer Healthcare Inc.同比增速更快（-2.4% vs -10.3%），过去两年Prestige Consumer Healthcare Inc.的营收复合增速更高（1.2% vs -8.1%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
PBH vs RBBN — 直观对比
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $162.6M |
| 净利润 | $46.7M | $89.1M |
| 毛利率 | 55.5% | 42.9% |
| 营业利润率 | 29.1% | 37.6% |
| 净利率 | 16.5% | 54.8% |
| 营收同比 | -2.4% | -10.3% |
| 净利润同比 | -23.5% | — |
| 每股收益（稀释后） | $0.97 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $162.6M | ||
| Q4 25 | $283.4M | $227.3M | ||
| Q3 25 | $274.1M | $215.4M | ||
| Q2 25 | $249.5M | $220.6M | ||
| Q1 25 | $296.5M | $181.3M | ||
| Q4 24 | $290.3M | $251.4M | ||
| Q3 24 | $283.8M | $210.2M | ||
| Q2 24 | $267.1M | $192.6M |
| Q1 26 | — | $89.1M | ||
| Q4 25 | $46.7M | — | ||
| Q3 25 | $42.2M | $-12.1M | ||
| Q2 25 | $47.5M | $-11.1M | ||
| Q1 25 | $50.1M | $-26.2M | ||
| Q4 24 | $61.0M | — | ||
| Q3 24 | $54.4M | $-13.4M | ||
| Q2 24 | $49.1M | $-16.8M |
| Q1 26 | — | 42.9% | ||
| Q4 25 | 55.5% | 53.3% | ||
| Q3 25 | 55.3% | 50.1% | ||
| Q2 25 | 56.2% | 49.6% | ||
| Q1 25 | 57.3% | 45.4% | ||
| Q4 24 | 55.5% | 55.7% | ||
| Q3 24 | 55.5% | 52.1% | ||
| Q2 24 | 54.7% | 50.8% |
| Q1 26 | — | 37.6% | ||
| Q4 25 | 29.1% | 4.1% | ||
| Q3 25 | 29.1% | 1.3% | ||
| Q2 25 | 28.8% | 1.9% | ||
| Q1 25 | 29.8% | -10.8% | ||
| Q4 24 | 31.7% | 13.2% | ||
| Q3 24 | 29.7% | -0.4% | ||
| Q2 24 | 27.0% | -1.0% |
| Q1 26 | — | 54.8% | ||
| Q4 25 | 16.5% | — | ||
| Q3 25 | 15.4% | -5.6% | ||
| Q2 25 | 19.0% | -5.0% | ||
| Q1 25 | 16.9% | -14.5% | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 19.2% | -6.4% | ||
| Q2 24 | 18.4% | -8.7% |
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.97 | $0.50 | ||
| Q3 25 | $0.86 | $-0.07 | ||
| Q2 25 | $0.95 | $-0.06 | ||
| Q1 25 | $1.00 | $-0.15 | ||
| Q4 24 | $1.22 | $0.05 | ||
| Q3 24 | $1.09 | $-0.08 | ||
| Q2 24 | $0.98 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $67.6M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $1.8B | $419.1M |
| 总资产 | $3.5B | — |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $67.6M | ||
| Q4 25 | $62.4M | $96.4M | ||
| Q3 25 | $119.1M | $74.8M | ||
| Q2 25 | $139.5M | $60.5M | ||
| Q1 25 | $97.9M | $71.2M | ||
| Q4 24 | $50.9M | $87.8M | ||
| Q3 24 | $51.5M | $37.2M | ||
| Q2 24 | $34.3M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $342.1M | ||
| Q3 25 | $993.1M | $344.3M | ||
| Q2 25 | $992.7M | $346.5M | ||
| Q1 25 | $992.4M | $347.4M | ||
| Q4 24 | $992.0M | $348.3M | ||
| Q3 24 | $1.1B | $349.1M | ||
| Q2 24 | $1.1B | $350.0M |
| Q1 26 | — | $419.1M | ||
| Q4 25 | $1.8B | $449.0M | ||
| Q3 25 | $1.8B | $360.1M | ||
| Q2 25 | $1.9B | $370.4M | ||
| Q1 25 | $1.8B | $381.8M | ||
| Q4 24 | $1.8B | $404.6M | ||
| Q3 24 | $1.7B | $395.5M | ||
| Q2 24 | $1.7B | $405.0M |
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $1.2B | ||
| Q3 25 | $3.4B | $1.1B | ||
| Q2 25 | $3.4B | $1.1B | ||
| Q1 25 | $3.4B | $1.1B | ||
| Q4 24 | $3.3B | $1.2B | ||
| Q3 24 | $3.3B | $1.1B | ||
| Q2 24 | $3.3B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | 0.76× | ||
| Q3 25 | 0.54× | 0.96× | ||
| Q2 25 | 0.54× | 0.94× | ||
| Q1 25 | 0.54× | 0.91× | ||
| Q4 24 | 0.55× | 0.86× | ||
| Q3 24 | 0.61× | 0.88× | ||
| Q2 24 | 0.65× | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | — |
| 自由现金流经营现金流 - 资本支出 | $75.3M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 1.68× | — |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $78.3M | $29.2M | ||
| Q3 25 | $57.5M | $26.5M | ||
| Q2 25 | $79.0M | $-795.0K | ||
| Q1 25 | $61.8M | $-3.5M | ||
| Q4 24 | $65.1M | $61.8M | ||
| Q3 24 | $69.8M | $-14.8M | ||
| Q2 24 | $54.8M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | $75.3M | $27.3M | ||
| Q3 25 | $55.4M | $21.0M | ||
| Q2 25 | $78.2M | $-6.5M | ||
| Q1 25 | $58.4M | $-15.7M | ||
| Q4 24 | $63.5M | $53.8M | ||
| Q3 24 | $67.8M | $-23.7M | ||
| Q2 24 | $53.6M | $-12.9M |
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 12.0% | ||
| Q3 25 | 20.2% | 9.7% | ||
| Q2 25 | 31.3% | -2.9% | ||
| Q1 25 | 19.7% | -8.7% | ||
| Q4 24 | 21.9% | 21.4% | ||
| Q3 24 | 23.9% | -11.3% | ||
| Q2 24 | 20.1% | -6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 0.9% | ||
| Q3 25 | 0.8% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 1.2% | 6.7% | ||
| Q4 24 | 0.5% | 3.2% | ||
| Q3 24 | 0.7% | 4.2% | ||
| Q2 24 | 0.4% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
